VEGFA and age-related macular degeneration: Since the advent of second-generation VEGF inhibitors in 2020, the treatment of exudative AMD has shifted from first-generation agents, such as ranibizumab and aflibercept 2 mg, to second-generation agents, including brolucizumab and faricimab.